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1. Introduction 
Extended spectrum beta-lactamase (ESBL) and 
AmpC-producing E. coli continue to spread in in 
food producing animals. In 2013, the European 
Commission (EC) has taken the decision of 
including the isolation of ESBL and AmpC-
producing E. coli as mandatory parts of the EU 
monitoring which was started during 2015 and 
continued in 2016. The screening was 
performed during 2016 including both meat and 
caecal samples from poultry origin in the EU 
Member States and affiliated countries 
according to a common protocol defined by the 
EC and validated by the European Union 
Reference Laboratory for Antimicrobial 
Resistance (EURL-AR, 2014). Training on 
these protocols was provided in 2014 for all the 
involved National Reference laboratories 
(NRLs) and additional training was provided to 
two small groups of laboratories in 2015 and 
2016. 
In 2016 the EQAS was extended also to include 
carbapenemase and/or OXA-48-producing E. 
coli, thereby including the optional isolation of 
these using the EURL-AR selective isolation 
protocol on agar plates suitable for isolation of 
carbapenemase-producing E. coli.  
Similarly to the previous EURL-AR matrix 
based EQAS, the aim of this specific EQAS 
was to enhance the capacity of the laboratories 
in isolation, identification and antimicrobial 
susceptibility testing (AST) of ESBL/AmpC or 
carbapenemase-producing E. coli. Furthermore 
the results may be used to identify potential 
problems and/or focus areas for future 
training/education. 
Before October 2016 a preliminary study was 
conducted to prepare for the launch of this 
EQAS, using meat samples and caecal content 
matrices of poultry origin spiked with strains 
containing the resistance genes of interest.  
We launched this second EQAS matrix in 
October 2016. As mentioned above, this trial 
included isolation steps, confirmation of the ID 
as E. coli, MIC testing and confirmation of 
ESBL/AmpC and/or carbapenemase 
phenotypes by antimicrobial susceptibility 
testing on the second panel of antimicrobials. 
From January 2016, the laboratories should 
have implemented the methods and have 
started the monitoring on meat and caecal 
samples of poultry origin. Therefore the 
methods should have been implemented and 
validated at the NRL’s before this EQAS. The 
participation in this EQAS may be used to 
assess retrospectively the quality of data 
provided to the European Food Safety Agency 
(EFSA). 
No thresholds have been set in advance to 
evaluate the acceptance of the performance of 
the participating laboratories and therefore the 
results will not be classified as above or below 
a threshold, but evaluated case by case.  
The EQAS was organized by the EURL-AR at 
the National Food Institute (DTU Food), Kgs. 
Lyngby, Denmark. 
The data in this report are presented with 
laboratory codes. A laboratory code is known 
only by the individual laboratory, whereas the 
entire list of laboratories and their codes is 
confidential and known only by relevant 
representatives of the EURL-AR and the EU 
Commission. All conclusions are public.  
The technical advisory group of the EURL-AR 
EQAS scheme consists of competent 
representatives from all National Reference 
Laboratories for Antimicrobial Resistance 
(NRLs-AR), who meet annually at the EURL-AR 
workshop. 
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2. Materials and Methods  
2.1 Participants in EQAS 2016 
A pre-notification (App. 1), inviting the 
participants to the matrix EQAS 2016 was 
issued by e-mail to the EURL-AR network on 
the 23rd of August 2016. 
All participants were included in a participant list 
(App. 2) before the preparation and shipping of 
the samples. Participation was free of charge 
but each laboratory was expected to cover 
expenses associated with the analysis.  
2.2 Preparation of samples  
Eight samples were prepared and dispatched 
for isolation of ESBL, AmpC or carbapenemase 
-producing E. coli, including identification, and 
antimicrobial susceptibility testing (AST) of the 
obtained isolates. The samples included were 
both meat and caecal samples from poultry 
origin and were either artificially prepared to 
contain the test strains or unmodified.  
The meat used to prepare the samples was 
minced chicken meat acquired in local 
supermarkets (at least three batches were 
bought in sufficient amount for covering both 
the pre-tests and preparation of the samples). 
The meat was pretested using the official 
method for selective isolation of E. coli 
producing ESBL, AmpC or carbapenemase to 
ensure the batch used was negative for those 
and contained some background flora. A batch 
fulfilling these criteria was chosen for 
preparation of aliquots of 25 g of meat that were 
either directly used as blank samples or spiked 
as follows. 
The test isolates used in the spiking of meat 
samples within the EQAS matrix 2016 were 
prepared in advance and sub-cultured the day 
before sample preparation. For the sample 
preparation and standardization of the spiking, 
suspensions equal to McFarland 0.5 were 
prepared in saline tubes with the relevant 
isolates to contain about 108 CFU/mL, as 
confirmed by viable counts of serial dilutions on 
Luria Bertrani (LB) agar plates. The 
standardized suspensions were further diluted 
in tenfold dilutions and the meat samples (25 g) 
were spiked with 25 µl of the chosen dilutions. 
The spiking dilutions were chosen based on the 
stability of the results obtained in a pilot test 
performed before the EQAS sample 
preparation. This pilot was performed with 
samples spiked with the intended test strains 
and aimed at testing the stability of the 
inoculum in the samples and defining the 
concentrations to use in the EQAS to maximise 
the sensitivity of detection but without 
compromising sample stability. The final 
inoculum found in the samples in this EQAS 
was expected to be circa 103 CFU/g of meat, 
for the samples M-2.1, M-2.2, M-2.4 and M-2.5, 
whereas the sample M-2.3 was spiked with a 
lower amount of about 100 CFU/g of the test 
strain. The sample M-2.1 was spiked as 
mentioned above, however with a susceptible 
E. coli strain (ATCC 25922) and therefore 
expected to be negative. 
For the caecal samples, one slaughterhouse 
provided us with four batches of caeca from 
poultry (named as A-D) and the amount per 
batch was ranging between 140-300g (so all 
samples could be prepared from one single 
batch of matrix). The batches were tested 
individually using the official selective isolation 
protocol for ESBL, AmpC and carbapenemase -
producing E. coli. One negative caecal batch 
(batch C) was chosen to prepare all the caecal 
samples for the EQAS. Thereby 1g of caecal 
content was spiked with 10 µl of a dilution 
containing 106 CFU/ml and therefore the 
expected spiking level was 104 CFU/g for 
samples M-2.6 and M-2.7, while sample M-2.8 
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was kept as blank.  
The minimal inhibitory concentrations (MIC) of 
selected antimicrobials were determined using 
broth microdilution method at both for the 
strains used for spiking during the preparation 
work and for the isolates obtained in the 
homogeneity testing after sample preparation to 
generate expected results (App 3).and the 
genes identified in the spiking isolates were 
detected using PCR for the expected ESBL, 
AmpC and carbapenemase genes on the 
isolates obtained from the isolation procedure 
performed on the samples.  
For following up on the stability of the samples 
after shipping, repeated testing was performed 
of one set including the eight samples in four 
timepoints after shipment (during two weeks). In 
this period the meat samples were kept frozen 
at -80°C and the caecal samples were kept at 
4°C. 
2.3 Isolation and identification of 
ESBL, AmpC or carbapenemase 
producing E. coli from meat and 
caecal samples  
The official protocols for selective isolation and 
identification of the ESBL, AmpC and/or 
carbapenemase-producing E. coli isolates 
contained in the samples were available on the 
EURL website, http://www.eurl-ar.eu (App. 4a 
and 4b). For the identification of E. coli species 
different methods were allowed as these are 
not specified in the EU Commission 
implementing decision on the monitoring and 
reporting Antimicrobial resistance in zoonotic 
and commensal bacteria 2013/652/EU). The 
description of the method used for selective 
isolation of presumptive ESBL, AmpC or 
carbapenemase-producing E. coli as well as 
species identification was requested as part of 
the methods sheet to be completed in the 
database upload system. 
2.4 Antimicrobial susceptibility 
testing 
The panels of antimicrobials recommended for 
AST in this trial are those included in the EU 
Commission implementing decision on the 
monitoring and reporting Antimicrobial 
resistance in zoonotic and commensal bacteria 
2013/652/EU) (Table 1). 
Guidelines for performing the antimicrobial 
susceptibility testing using dilution methods 
were set according to the Clinical and 
Laboratory Standards Institute (CLSI) document 
– M7-A10 (2015) “Methods for Dilution 
Antimicrobial Susceptibility Tests for Bacteria 
That Grow Aerobically; Approved Standard - 
tenth Edition”” and whenever commercial 
methods were used, the guidelines of the 
manufacturer were followed.  
MIC results were interpreted by using EUCAST 
epidemiological cut-off values 
(www.eucast.org), as included in the regulation 
referred above or as recommended by EFSA 
and described in the EQAS protocol (App. 4). 
Results of the ESBL confirmatory testing were 
interpreted according to the recommendations 
by EFSA and as referred in the regulation, 
using MIC testing on the second panel of 
antimicrobials, which is intended to be used 
every time a strain is found resistant to either 
cefotaxime, ceftazidime or meropenem.  
2.5 Distribution 
The meat samples were frozen at -80°C and 
kept at this temperature after preparation and 
until shipment. The caecal samples were sent 
short after preparation, and therefore kept at 
4°C until shipment. At the day of shipment, the 
samples were tightly packed in thermoboxes 
with cooling elements frozen at -80°C. The 
parcels contained the eight samples in tubes, 
and an additional tube contained a 
thermologger to register the temperature at 15 
min intervals during transport. Furthermore, the 
parcel contained a welcome letter with the login 
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and password to the web based database for 
the data upload and a labelled envelope for 
returning the thermologger to the EURL-AR. 
The protocol for the EQAS and the test forms 
were made available online on the EURL-AR 
website, http://www.eurl-ar.eu, before launching 
this EQAS. 
The thermoboxes used for the shipment of 
samples were enclosed in double pack 
containers and sent to the selected laboratories 
according to the International Air Transport 
Association (IATA) regulations as “Biological 
Substance category B” classified UN3373. The 
parcels were dispatched from DTU-Food 
October 10th, 2016. 
The laboratories were instructed to download 
the protocol and test forms (App. 4 and 5), from 
http://www.eurl-ar.eu and to process the 
samples following the EU protocol for selective 
isolation of presumptive ESBL, AmpC and/ 
carbapenemase producing E. coli from either 
meat or caecal samples, precisely as they 
would normally do for the EFSA monitoring. For 
the results collection the NRLS were instructed 
to upload of the data in the web based 
database, which was designed and prepared 
for this EQAS and opened shortly after sample 
shipment and until the deadline. 
After completion of the tests, the laboratories 
were requested to enter the obtained results 
into the electronic sheet in the EURL-AR web 
based database through a secured individual 
login (App 5). The database was activated on 
the 3rd November 2016, and closed December 
15th 2016. 
For the first part of the results of the selective 
isolation procedure for ESBL /AmpC and for 
carbapenemases, the results obtained from the 
isolation procedures samples were evaluated 
separately by defining the samples as positive if 
an isolate was obtained and positively identified 
as E. coli. Additionally, the results of 
susceptibility testing of the obtained isolates 
using both MIC panels were analysed 
separately in similar way as to the similarly to 
the E. coli AST EQAS, including the read 
values of MIC and their interpretations. As a 
conclusion of the susceptibility testing, the 
participants were asked to classify the isolates 
obtained according to the defined EFSA criteria 
Table 1. Panel of antimicrobials recommended for susceptibility testing of bacteria included in this EQAS 2016 component 
Escherichia coli Escherichia coli 
2nd panel 
Ampicillin, AMP Cefepime, FEP 
Azithromycin, AZI Cefotaxime + clavulanic acid (F/C) 
Cefotaxime, FOT Cefotaxime, FOT 
Ceftazidime, TAZ Cefoxitin, FOX 
Chloramphenicol, CHL Ceftazidime, TAZ 
Ciprofloxacin, CIP Ceftazidime+ clavulanic acid (T/C) 
Colistin, COL Ertapenem, ETP 
Gentamicin, GEN Imipenem, IMI 
Meropenem, MERO Meropenem, MERO 
Nalidixic acid, NAL Temocillin, TRM 
Sulfamethoxazole, SMX  
Tetracycline, TET  
Tigecycline, TGC  
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for interpretation of ESBL/Ampc and/or 
carbapenemase producing isolates. 
After the deadline, the qualitative results 
indicating if the samples were positive or 
negative for ESBL/AmpC, or carbapenemase-
producing E. coli (OXA-48 and other), as well 
as the interpretations of the susceptibility tests 
results, and the conclusion on the observed E. 
coli phenotypes were evaluated against the 
expected results and scored as correct or 
incorrect. As no threshold is agreed the 
performance was evaluated case by case and 
not classified into acceptable or unacceptable 
based on the deviation percentage.  
3. Results 
A total of 33 parcels were sent to the 34 
laboratories that participated in the EQAS; 
including 31 participant laboratories 
representing the NRLs from all 28 MS (please 
note that for three MS the samples were divided 
by type between two laboratories), and 
laboratories from Norway, Switzerland and 
Iceland responded to the pre-notification and 
were additionally enrolled in the EQAS. Two 
additional non-NRL laboratories from EU were 
enrolled and provided results but were not 
included further in the report. For more 
information on the countries participating 
consult the map below (Figure 1).  
When the deadline was reached, 33 sets of 
data representing the 34 enrolled laboratories 
were uploaded for the samples tested, thus all 
participating countries had one complete set of 
data.  
As requested, the participating laboratories 
have, returned the thermologgers to the EURL. 
Here the registration of the temperature was 
extracted and read to provide the temperature 
ranges along the shipment and at sample 
reception/opening. Furthermore, the 
participants were requested to provide more 
information in a small introductory questionnaire 
on the database, including details on sample 
reception (measured temperature and 
date/time), the monitoring activities, and the 
methods used in their laboratory. 
The temperature data were analysed at the 
EURL and showed a range of temperatures 
between -10°C and 10°C for measures taken by 
the participants, and -14.5°C and 7°C, when 
inferred from the temperature at opening time 
from the thermologger registration (Figure 2). 
This showed that most laboratories measured 
temperatures above those registered in the 
logger, however when looking at the logger 
temperatures most samples were expected to 
be in good conditions for testing at opening of 
the samples, and all samples were tested, 
independently of the temperature measured by 
the participants. In a few cases (Labs #29, #37, 
#41 and #58) it was not possible to correctly 
estimate the temperature at sample processing 
as the sample was probably not processed 
immediately, but kept in refrigeration or frozen 
from reception to the start of processing of 
samples as the thermologger data indicates 
there was a storage period. 
3.1 Methods used by EQAS-
participants 
All 33 participating laboratories which have 
submitted results participated in the ESBL and 
AmpC isolation and performed the identification 
and susceptibility of the respective isolates. The 
number of qualitative isolation tests results 
reported was variable including results for three 
to eight samples, depending on how many 
samples were tested (a few participants only 
tested meat or caecal sample while others 
tested both), for the antimicrobial susceptibility 
test it depended on how many isolates were 
found and further tested in the MIC panels. The 
number of AST tests performed in ranged from 
44 to 132 tests per participant.  
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Information on the methods used for isolation, 
identification and typing was collected from the 
participants through the database.  
Most laboratories (n=32) reported that isolation 
has been performed following the exact 
procedures described in the protocol provided 
One participant reported that the incubation 
was processed at 41.5°C instead of 44° and 
20h. 
The species identification testing was 
performed using MALDI TOF in the majority of 
the laboratories (n=12), followed by biochemical 
tests (n=11), chromogenic agar plating (n=7), 
and PCR using specific targets to confirm the 
ID (n=3). Additionally many laboratories 
reported using second and third identification 
 
Figure 1. Countries participating in EQAS matrix 2016. 
 
Figure 2. Temperatures measured at reception/opening measured by own measurement (Temp mes) 
and obtained from temperature logger (Temp log) in parcels for EQAS matrix 2016. 
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methods as supplementary. 
The broth microdilution testing was performed 
using the antimicrobials and ranges defined 
under the EU Commission regulation 652/2013 
for testing the isolated and identified E. coli 
isolates using panel 1 (EUVSEC) additional 
AST of the presumptive ESBL/AmpC and/or 
carbapenemase isolates was performed using 
panel 2 (EUVSEC2) if relevant and 
interpretation of the results according to the 
EFSA criteria for ESBL/AmpC and 
carbapenemase phenotypic classification. One 
participant (Lab #37) performed the testing 
using agar dilution testing of the same range of 
antimicrobials and concentrations. 
3.2 ESBL /AmpC and 
carbapenemase producing E. coli 
isolation and identification 
ESBL/AmpC 
The total amount of test results was 248 tests 
for the ESBL/AmpC isolation qualitative results. 
In this trial, twenty six participating NRL’s 
reported results for all the eight samples sent. 
Two laboratories reported only results for the 
meat samples (Labs, #38, and #41) and two 
laboratories reported only results for the caecal 
samples (Labs #32 and #58). Lab #4 uploaded 
results for all eight samples tested in the 
country, but tests of meat and caecal samples 
were performed in two different locations. All in 
all 247 tests were correct, corresponding to 
99.6% of correct results (and 0.4% deviations). 
From the 62 samples expected to be negative 
all were correctly assigned. Regarding the 186 
samples expected to be found positive, all but 
one were correctly found positive. Only one 
deviation was observed by Lab #37 that 
considered the caecal sample M-2.7 as 
negative (Table 2).  
 
Other carbapenemases and OXA-48 
The specific isolation of presumptive 
carbapenemase producing E. coli was 
performed by extending the protocol by addition 
of isolation on CARBA selective agar plates as 
described in the EURL-AR protocols. In total 
233 tests results were submitted. Please note 
that even though 33 sets of results were 
submitted, eight of the laboratories did not 
Table 2. The overall performance of ESBL/AmpC isolation and identification, 2016. 
Isolation of ESBL /AMPC from samples  Correctly classified samples 
Number of performed tests Number of correct tests N(%) 
N % N % 
248 100 247 99.6 
Number of expected negative tests Number of correctly identified negative tests 
N % N % 
62 25 62 100 
Number of expected positive tests Number of correctly identified positive tests 
N % N % 
186 75 185 99.5 
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actually perform the specific isolation procedure 
for carbapenemase –producing E. coli, but 
defined results based on the findings with the in 
the ESBL/ampC selective method and thereby 
reported results for one to eight samples while 
the remaining 25 laboratories used the exact 
protocol as defined by the EURL-AR. The 
plates used for this purpose were chosen by the 
laboratories as the protocol defines that any 
suitable plates for selective isolation of 
carbapenemase- and OXA-48-producing E. coli 
may be used. Most participants declared the 
use of the chromogenic agar Chrom ID CARBA 
and Chrom ID OXA or CARBA smart 
combination plates (as reported by eight and 
five participants, respectively) only one 
participant used Liofilchem plates (Lab #23). A 
total of 11 participants did not report the brand 
of plates being used for this purpose, even 
though they report the EURL-AR protocol was 
followed. 
A total of 224 results were considered correct, 
meaning that nine deviating results were 
observed for the presumptive carbapenemase-
producing E. coli isolation. Eight of the 
deviations were due to false negative result of 
isolation from sample M-2.2 which contained a 
VIM-1 positive E.coli that should grow on the 
CARBA plate but was not detected by some of 
the participants (Labs #4, #11, #19, #25, #26, 
#40, #45, #56). The single remaining deviation 
was due to one false positive result of sample 
M-2.1 (lab #21) which is likely a transcription 
mistake as the comments refer that an isolate 
that was not identified as E. coli was isolated 
from this sample (Figure 3).  
All 233 OXA-48 results reported were correctly 
interpreted as negative. 
3.3 Antimicrobial susceptibility 
testing 
A total of 4049 tests results were uploaded and 
3976 (98.2%) of these were correct. All 33 labs 
uploaded a variable number of results, 
depending on the samples found positive and 
isolates tested in one or both panels, ranging 
from 44 to 132 test results per participant. 
The analysis per laboratory identified seven 
laboratories with no deviations while the others 
had deviation percentages ranging from 0.8% 
to 5.3% (Figure 4). As mentioned before, as the 
performance on the AST depends on the 
isolation and identification procedures no 
threshold was set for acceptance as the 
capacity for performing AST of E. coli is 
analysed more accurately in the E. coli AST 
EQAS. 
In the analysis of the results per antimicrobial 
we observed that the results showed the 
highest deviation percentage for cefoxitin 
(12.4%) followed by temocillin (6.2%) and 
cefepime (5.9%). This might be related to 
expected results lying close to the breakpoint. 
The remaining results per antimicrobial 
substance showed deviation levels below 5% 
(Figure 5). 
The analysis performed per sample indicates 
that the highest deviation level (4.0%, 27 
deviations) was observed for sample M-2.2, 
followed by sample 2.3 (2.8% deviations). All 
other samples had deviation levels below 2% 
(Figure 6). 
3.4 ESBL/AmpC phenotypic testing 
conclusions 
The sample M-2.2 contained a carbapenemase 
-producing (VIM-1) E. coli while samples M-2.3 
and M-2.6 contained ESBL producing strains 
carrying the blaTEM52 and blaSHV-12 genes, 
respectively. The samples M-2.4 and M-2.7 
contained isolates with AmpC phenotypes 
mediated by blaCMY-2. The sample M-2.5 
contained a strain which was both ESBL and 
AmpC (blaCTX-M-1 and blaCMY-2) and the 
remaining samples (M-2.1 and M-2.8) did not 
contain ESBL or AmpC presumptive isolates 
and were expected to be negative in the first 
part of the EQAS for the selective isolation. 
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Due to the mixed phenotypes obtained 
(because of the cefoxitin values close to the 
breakpoint) we decided that the option 
ESBL+AmpC would be accepted as correct as 
well as the option ESBL for the strains isolated 
from sample M 2.3 and 2.6 (Appendix 3). 
Of 185 results uploaded, 177 were correct 
(95.7%) and 8 (4.3%) were deviating. The most 
frequent deviation was related to sample 2.5 
where the isolated strain had both ESBL and 
AmpC encoding genes and four participants 
only identified the AmpC phenotype (Labs #11, 
#20, #25, #45). Two deviations were caused by 
lack of identification of the carbapenemase in 
sample 2.2 (Labs #19 and #26) and the 
remaining were related to sample 2.3 identified 
as presumptive AmpC and thereby missing the 
ESBL phenotype which should have been 
noticed by the detection of synergy in the tests 
with clavulanic acid (Lab #42) and sample 2.4 
which contained an AmpC gene was reported 
as ESBL+AmpC in one instance (Lab #41). 
Figure 3. Results of carbapenemase isolation per participant laboratory in the EQAS matrix 2016. 
 
Figure 4. Results of antimicrobial susceptibility testing per participanting laboratory in the EQAS matrix 2016. 
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4. Discussion
4.1 ESBL and AmpC and 
carbapenemase-producing E. coli 
isolation and identification 
The 2016 EURL-AR matrix EQAS trial was the 
second of this kind and as it was run with 
samples of different origin compared to the first 
one. It was still challenging in the setting up and 
planning the sample preparation, however the  
results were overall mostly correct according 
to expected, both regarding the isolation and 
AST parts, with all except one of the  
ESBL/AmpC isolation results correct. 
Most of the carbapenemase isolation results 
 
Figure 5- Number of deviations per antimicrobial in EQAS matrix 2016 (AST results). 
 
Figure 6- Number of deviations per sample in EQAS matrix 2016 (AST results). 
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14 
were found correct, however still eight labs 
were not able to isolate the sample 2.2 VIM-1 
positive isolate and one additional and found 
one false positive isolate in sample 2.1. 
4.2 Antimicrobial susceptibility 
testing 
The results uploaded were in general according 
to expected even though in such a trial 
challenges could have occurred in retrieving the 
right isolates from the samples, or changes 
could have occurred in the isolate composition 
in the samples or the isolate characteristics 
(conjugation, or plasmid losses). Some of the 
deviating results were caused by results lying 
close to breakpoint. 
4.3 ESBL /AmpC phenotypic testing 
conclusions 
As what regards to the final conclusions for the 
AST testing and phenotypic confirmation, the 
conclusions depends heavily on the isolation 
process, thus some of the deviations might be 
related to the isolation of isolates that have 
different characteristics. However, we noticed 
that most deviations in this part were related to 
the lack of identification of the carbapenem 
resistance and problems with detection of the 
mixed ESBL+AmpC phenotypes in distinction of 
the simple ESBL or AmpC phenotypes.  
 
5. Conclusion 
In general, the results of this matrix EQAS 
demonstrate that most participating labs have 
set up the methods and are able to isolate 
ESBL and AmpC carrying strains from meat or 
caecal samples in a reliable fashion. However 
the results were less good for the selective 
isolation of carbapenemase -producing isolates 
using selective media. There is some need to 
strictly control the media and the procedures of 
the selective isolation procedure to select ESBL 
and AmpC or carbapenemase -producing E. 
coli and to do species identification with reliable 
methods to allow detection of all relevant 
isolates with increased sensitivity. 
The susceptibility testing results were in general 
according to expected, however a relatively 
number of deviations were observed than in 
other AST EQAS and this might be related with 
the fact that the results of AST being 
dependent on the performance in the 
isolation, but also due to few tests results 
lying very close to the breakpoint and 
therefore leading to differences in the 
interpretations. 
 
 
6. References
EC 652/2013- COMMISSION IMPLEMENTING 
DECISION of 12 November 2013 on the 
monitoring and reporting of antimicrobial 
resistance in zoonotic and commensal bacteria. 
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Appendix 1- EURL-AR EQAS pre-notification 
G00-06-001/01.12.2014 
 
EQAS 2016 FOR SELECTIVE ISOLATION OF E. COLI WITH PRESUMPTIVE ESBL, 
AMPC PHENOTYPES OR CARBAPENEMASES FROM MEAT OR CAECAL SAMPLES 
The EURL-AR announces the launch of the second EQAS on matrix samples, providing the 
opportunity for proficiency testing which is considered an essential tool for the generation of 
reliable laboratory results of consistently good quality. 
This EQAS consists of testing of eight samples for selective isolation of ESBL, AmpC or 
carbapenemase-presumptive E. coli. 
This EQAS is specifically for NRL’s on antimicrobial resistance involved in the monitoring 
according to the EU Commission legislation 652/2013 and specifically processing meat and caecal 
samples in the specific monitoring for ESBL implemented in 2015. Previously to this 
prenotification, the laboratories designated to be NRL-AR have been contacted to confirm the 
addresses for the shipment of these samples. Participation is free of charge for all above-mentioned 
designated laboratories.  
TO AVOID DELAY IN SHIPPING THE ISOLATES TO YOUR LABORATORY 
The content of the parcel is categorized as “UN3373, Biological Substance Category B”. Eight 
samples which might contain ESBL, AmpC or carbapenemase-producing E. coli included in a 
matrix of meat and/or caecal will be shipped. Please provide the EQAS coordinator with documents 
or other information that can simplify customs procedures (e.g. specific text that should be written 
on the proforma invoice). To avoid delays, we kindly ask you to send this information already at 
this stage.  
TIMELINE FOR RESULTS TO BE RETURNED TO THE NATIONAL FOOD INSTITUTE 
Shipment of isolates and protocol: The isolates are expected to be shipped in the second week of 
October. The protocol for this proficiency test will be available for download from the website 
(www.eurl-ar.eu  ).  
Submission of results: Results must be submitted to the National Food Institute no later than 
December, 9th, 2016 via a password-protected website. Upon reaching the deadline, each 
participating laboratory is kindly asked to enter the password-protected website once again to 
download an automatically generated evaluation report. 
EQAS report: A report summarising and comparing results from all participants will be issued. In 
the report, laboratories will be presented coded, which ensures full anonymity. The EURL-AR and 
the EU Commission, only, will have access to un-coded results. The report will be publicly 
available. 
 
Next EQAS: The next EURL-AR EQAS that we will have is on antimicrobial susceptibility testing 
of E. coli, staphylococci and enterococci which will be carried out in June, 2017.  
Please contact me if you have comments or questions regarding the EQAS. 
Sincerely, 
Lina Cavaco 
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List of participants 
Institute  Country  Meat Caecal 
Austrian Agency for Health and Food Safety  Austria  X X 
ARSIA (reported by the Institute of Public Health)  Belgium   X 
Institute of Public Health  Belgium  X   
National Centre of Food Safety  Bulgaria  X  X 
Croatian Veterinary Institut  Croatia  X  X 
Veterinary Services  Cyprus  X  X 
State Veterinary Institute Praha  Czech Republic  X  X 
Danish Veterinary and Food Administration, DVFA  Denmark  X  X 
Estonian Veterinary and Food Laboratory  Estonia  X  X 
Finnish Food Safety Authority EVIRA  Finland  X  X 
ANSES ‐ Laboratoire de Fougères LERMVD  France  X  X 
Federal Institute for Risk Assessment  Germany  X  X 
Veterinary Laboratory of Chalkis  Greece  X  X 
Central Agricultural Office Veterinary Diagnostic Directorate  Hungary  X  X 
Institute For Experimental Pathology, University of Iceland, KELDUR  Iceland  X  X 
Central Veterinary Research Laboratory  Ireland  X  X 
Istituto Zooprofilattico Sperimentale delle Regioni Lazio e Toscana  Italy  X  X 
Institute of Food Safety, Animal Health and Environment "BIOR"  Latvia  X  X 
National Food and Veterinary Risk Assessment Institute  Lithuania  X  X 
Laboratoire de Medecine Vétérinaire  Luxembourg  X  X 
Public Health Laboratory  Malta  X  X 
Central Veterinary Institute of Wageningen UR  Netherlands  X  X 
Food and Consumer Product Safety Authority (VWA)  Netherlands  X  X 
Veterinærinstituttet  Norway  X  X 
National Veterinary Research Institute  Poland  X  X 
Laboratorio National de Investigacáo Veterinaria  Portugal  X  X 
Institute for Diagnosis and Animal Health  Romania   X 
Institute for Hygiene and Veterinary Public Health  Romania  X   
State Veterinary and Food Institute  (SVFI)  Slovakia  X  X 
National Veterinary Institute  Slovenia  X  X 
Centro Nacional de Alimentación (AECOSAN)  Spain  X   
Laboratorio Central de Sanidad, Animal de Algete  Spain   X 
VISAVET Health Surveillance Center, Complutense University  Spain  X  X 
National Veterinary Institute, SVA  Sweden  X  X 
Vetsuisse faculty Bern, Institute of veterinary bacteriology  Switzerland  X  X 
Animal and Plant Health Agency (APHA)  United Kingdom  X  X 
      
NRL's 
non‐ NRL enrolled for  EQAS 
not EU‐member state 
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Appendix 3 - Expected results for the matrix trial 2016 
Qualitative results  
 
 Meat 
Sample  Gene background  Expected results selection ESBL /AmpC 
Expected results 
selection CARBA 
Expected results 
selection OXA‐48  CFU per 25 g  CFU/g meat 
EURL‐M‐2.1 
None (ATCC 
strain)  Negative  Negative  Negative  2,5 x 10
4  1 x 103 
EURL‐M‐2.2  VIM‐1  Positive  Positive  Negative  2,5 x 104  1 x 103 
EURL‐M‐2.3  TEM 52  Positive  Negative  Negative  2,5 x 103  100 
EURL‐M‐2.4  CMY‐2  Positive  Negative  Negative  2,5 x 104  1 x 103 
EURL‐M‐2.5  CTX‐M‐1+CMY‐2  Positive  Negative  Negative  2,5 x 104  1 x 103 
 
 
Caecal 
Sample  Sample origin  Expected results selection ESBL /AmpC 
Expected results 
selection CARBA 
Expected results 
selection OXA‐48 
CFU/g caecal 
sample 
EURL‐M‐2.6  SHV‐12  Positive  Negative  Negative  1 x 104 
EURL‐M‐2.7  CMY‐2  Positive  Negative  Negative  1 x 104 
EURL‐M‐2.8  None  Negative  Negative  Negative  0 
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Susceptibility testing (MIC- values and interpretations) 
 
Panel 1 
Strain nr  Species  MERO  COL  AMP  AZI  TAZ  CHL  CIP  FOT  GEN  NAL  SMX  TET  TMP  TGC 
EURL‐M‐2.2  E. coli  0.5  <=1  >64  8  >8  <=8  <=0.015  >4  1  <=4  >1024  <=2  <=0.25  <=0.25 
EURL‐M‐2.3  E. coli  <=0.03  <=1  >64  8  >8  16  >8  >4  1  >128  >1024  >64  >32  <=0.25 
EURL‐M‐2.4  E. coli  <=0.03  <=1  >64  8  8  >128  0.5  >4  <=0.5  >128  >1024  64  >32  <=0.25 
EURL‐M‐2.5  E. coli  0.06  <=1  >64  8  >8  <=8  >8  >4  1  >128  >1024  >64  <=0.25  <=0.25 
EURL‐M‐2.6  E. coli  <=0.03  <=1  >64  8  >8  <=8  1  >4  <=0.5  8  >1024  4  0.5  <=0.25 
EURL‐M‐2.7  E. coli  <=0.03  <=1  >64  8  8  <=8  <=0.015  >4  1  <=4  16  <=2  0.5  <=0.25 
 
Strain nr  E. coli  MERO  COL  AMP  AZI  TAZ  CHL  CIP  FOT  GEN  NAL  SMX  TET  TMP  TGC 
EURL‐M‐2.2  E. coli  R  S  R  S  R  S  S  R  S  S  R  S  S  S 
EURL‐M‐2.3  E. coli  S  S  R  S  R  S  R  R  S  R  R  R  R  S 
EURL‐M‐2.4  E. coli  S  S  R  S  R  R  R  R  S  R  R  R  R  S 
EURL‐M‐2.5  E. coli  S  S  R  S  R  S  R  R  S  R  R  R  S  S 
EURL‐M‐2.6  E. coli  S  S  R  S  R  S  R  R  S  S  R  S  S  S 
EURL‐M‐2.7  E. coli  S  S  R  S  R  S  S  R  S  S  S  S  S  S 
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Susceptibility testing (MIC- values and interpretations), ctd. 
  
Panel 2 
Strain nr  Species  MERO  FEP  FOX  TAZ  FOT  T/C  F/C  IMI  ETP  TRM  ESBL conclusion 
EURL‐M‐2.2  E. coli  0.5  16  64  128  >64  128  >64  2  0.25  64  CARBA 
EURL‐M‐2.3  E. coli  <=0.03  2  16  16  8  0.25  0.25  0.12  <=0.015  16  ESBL (or ESBL+AmpC)* 
EURL‐M‐2.4  E. coli  <=0.03  0.25  32  8  8  8  8  0.25  0.03  4  AmpC 
EURL‐M‐2.5  E. coli  <=0.03  8  32  32  >64  8  8  0.25  0.03  8  ESBL+AmpC 
EURL‐M‐2.6  E. coli  <=0.03  1  8  32  8  0.25  0.12  0.25  <=0.015  8  ESBL (or ESBL+AmpC)* 
EURL‐M‐2.7  E. coli  <=0.03  0.12  32  8  8  4  4  0.25  0.03  8  AmpC 
 
Strain nr  Species  MERO  FEP  FOX  TAZ  FOT  T/C  F/C  IMI  ETP  TRM 
EURL‐M‐2.2  E. coli  R  R  R  R  R  NA  NA  R  R  R 
EURL‐M‐2.3  E. coli  S  R  R  R  R  NA  NA  S  S  S 
EURL‐M‐2.4  E. coli  S  R  R  R  R  NA  NA  S  S  S 
EURL‐M‐2.5  E. coli  S  R  R  R  R  NA  NA  S  S  S 
EURL‐M‐2.6  E. coli  S  R  S  R  R  NA  NA  S  S  S 
EURL‐M‐2.7  E. coli  S  S  R  R  R  NA  NA  S  S  S 
 
   Resistant 
 NA   Not applicable or not testet 
Abbreviations: AMP ‐ ampicillin, AZI ‐ Azithromycin, CHL ‐ chloramphenicol, CIP ‐ ciprofloxacin, COL ‐ colistin, ETP ‐ ertapenem, FEP ‐ cefepime,  FOT‐ cefotaxime, FOT/CLA ‐ 
cefotaxime/clavulanic acid, GEN‐ gentamicin, IMI ‐ imipenem, MER‐ meropenem, NAL ‐ nalidixic acid, SMX ‐ sulfamethoxazole, TAZ ‐ ceftazidime, TAZ/CLA ‐ 
ceftazidime/clavulanic acid, TET ‐ tetracycline, TMP ‐ trimethoprim, TGC ‐ tigecycline, TRM ‐ temocillin. 
 
*Regarding the interpretations, see page 14 in the report 
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PROTOCOL  
for selective isolation of presumptive ESBL-, AmpC- and carbapenemase-producing 
Escherichia coli from meat and caecal samples (matrix EQAS) 
 
Table of contents 
1  INTRODUCTION .................................................................................................................. 1 
2  OBJECTIVES ........................................................................................................................ 2 
3  OUTLINE OF THE EQAS ................................................................................................... 2 
3.1  Shipping, receipt and storage of samples ................................................................ 2 
3.2  Selective isolation of ESBL, AmpC or carbapenemase producing E. coli from the 
samples .................................................................................................................................. 3 
3.3  Antimicrobial susceptibility testing ......................................................................... 3 
4  REPORTING OF RESULTS AND EVALUATION .......................................................... 6 
4.1  General recommendations for data upload ............................................................ 6 
5  HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE ............................ 6 
5.1  Sample reception/testing........................................................................................... 6 
5.2  Selective enrichment methods .................................................................................. 7 
5.3  Test results ................................................................................................................. 7 
5.4  Finalizing data input, EQAS evaluation and approval of result upload ............. 7 
APPENDIX ......................................................................................................................................... 9 
 
 
1 INTRODUCTION 
The organisation and implementation of an External Quality Assurance System (EQAS) on 
selective isolation of presumptive extended spectrum beta-lactamase (ESBL)-, AmpC- or 
carbapenemase-producing E. coli is among the tasks of the EU Reference Laboratory for 
Antimicrobial Resistance (EURL-AR), and will include the selective isolation procedures and 
antimicrobials susceptibility testing (AST) of obtained isolates of eight samples of either meat or 
caecal content. In 2016, these eight samples will include five samples of 25g meat and three 
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samples of 1g of caecal content, both of poultry origin. These samples may or may not contain E. 
coli presumptive of producing either ESBL-, AmpC- or carbapenemase-enzymes.  
It is expected that the participating laboratories for the analyses apply the same procedures used in 
the monitoring described by the regulation EC/652/2013, and perform the selective isolation 
following the EU recommended methods published on the EURL-AR website www.eurl-ar.eu.  
2 OBJECTIVES 
This EQAS aims to assess and, if necessary, to improve the quality of results obtained in the 
selective isolation of presumptive ESBL-, AmpC- or carbapenemase-producing isolates from meat 
and caecal samples. Further objectives are to evaluate and improve the comparability of 
surveillance data on ESBL-, AmpC- or carbapenemase -producing E. coli reported to EFSA by 
different laboratories. 
3 OUTLINE OF THE EQAS 
3.1 Shipping, receipt and storage of samples 
In October 2016, the National Reference Laboratories for Antimicrobial Resistance (NRL-AR) will 
receive a parcel containing eight samples from the National Food Institute. All strains used in the 
spiking of samples belong to UN3373, Biological substance, category B. Participants should expect 
that ESBL-, AmpC- and/or carbapenemase-enzymes producing strains will be included in some of 
the sample matrix. 
The samples will be either 25g of meat (spiked matrix) or 1g of caecal content and will be 
distributed already weighed and ready to be tested, in tubes labelled from 2.1 to 2.8 (2.1 to 2.5 
being samples with 25g meat and 1.6 to 1.8 being samples containing 1g each of caecal content) 
The samples will be shipped in frozen state in tubes and contained in cooling boxes with 
temperature control devices and cooling elements.  
Upon reception it is very important to open the parcel as soon as possible and proceed to the 
analysis (following the normal procedures for sample testing in the monitoring).  
It is required that participants  
- when opening the parcel, note the date and exact time at opening (this data is very 
important to follow the temperature data checks) 
- proceed to sample analysis immediately after opening the parcel 
- register the date for analysis start for each sample 
- collect the temperature control device (small discoid device located in a bag inserted in 
a labelled tube, located inside the parcel); open the tube and take out the bag with the 
device inside. Place this bag with the device in the labelled bubble envelope provided and 
send it back to the EURL-AR as soon as possible. Please note that you will have to arrange 
for stamps/postage (the post systems differ from country to country, why this cannot be 
arranged and paid from the EURL-AR in advance).  
Appendix 4 
Page 3 of 9 
Page 3 of 9 
  
 
3.2 Selective isolation of ESBL, AmpC or carbapenemase producing E. coli from the 
samples  
The samples provided in each parcel are weighed beforehand and therefore no further weighing is 
required. Proceed immediately to the first enrichment step by adding the sample to the necessary 
amount of media (225 ml of Buffered Peptone water for the meat samples and 9 ml for the caecal 
samples as referred in the official EURL-AR protocols. All the following procedures should follow 
the methods used in the monitoring for ESBL and AmpC E. coli according to the EC/652/2013 
regulation. If any changes are introduced to the official protocols, these changes should be 
described with details in the online database on the methods upload page. The participants are 
responsible for assuring the validity of the plates and therefore the protocol for “Validation of 
selective MacConkey agar plates supplemented with 1 mg/L cefotaxime for monitoring of ESBL 
and AmpC producing E. coli in meat and animals” should be run beforehand, as stated on the 
EURL-AR webpage (see http://eurl-ar.eu/233-protocols.htm). 
Optionally, the participants may perform the additional plating for isolation of carbapenemase-
producing E. coli from the samples, following the official protocols and plating on suitable agar 
plates. Similarly, the agar plates used for the carbapenemase isolation should be validated using the 
protocol for “Validation of selective and indicative agar plates for monitoring of carbapenemase-
producing E. coli”. 
The officially recommended protocols are found on the EURL-AR webpage (http://eurl-ar.eu/233-
protocols.htm): 
 Follow the protocol for meat when testing samples 2.1 to 2.5 
 Follow the protocol for caecal content when testing samples 2.6 to 2.8 
As referred in these protocols, the isolates obtained from isolation procedure should be identified as 
E. coli using the procedures for E. coli species identification applied at the participant’s laboratory 
for the specific monitoring of ESBL- and AmpC-producing E.coli. 
Please store the isolates obtained in the isolation procedure and document the whole process as well 
as all the findings in each step.  
As part of the results submission, you will be requested to describe the findings along the 
enrichment process and selective isolation including growth in the media, isolation of suspected 
colonies, species identification results and finally regarding the finding (or not) of presumptive E. 
coli isolates harbouring one of the selected resistances (this result will be evaluated in relation to the 
expected result as a qualitative result) (see details in the Test Form).  
3.3 Antimicrobial susceptibility testing 
If the sample is deemed positive for ESBL- , AmpC- or carbapenemase -producing E. coli, one E. 
coli isolate per sample should be taken further and tested for susceptibility to the antimicrobials as 
stated in the EU regulation (antimicrobials listed in Tables 1 and 2 in this document).  
Only one E.coli isolate is expected to be tested for AST and these results will be evaluated in the 
database against the expected results.  
AST results to be reported should be from: 
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 A presumptive carbapenemase positive isolate (from the CARBA or OXA-48 selective plates), 
if this optional part was performed and a presumptive carbapenemase positive E. coli isolate 
was detected.  
 An ESBL- or AmpC-presumptive isolate (if you do not have a carbapenemase positive isolate or 
if you did not perform the optional plating) if an ESBL- or AmpC-presumptive isolate was 
detected. 
 
The testing should be performed using the same method as implemented in your laboratory for 
performing AST when monitoring for EFSA according to the regulation EC/652/2013 (using the 
two-step approach, i.e. both testing panels) and applying the interpretative criteria listed below. 
 
Table 1. Antimicrobials recommended for AST of Escherichia coli and interpretative criteria 
according to table 1 in Commission Implementing Decision 2013/652/EU 
 
Antimicrobials for E. coli MIC (g/mL) R is > 
Ampicillin, AMP 8 
Azithromycin, AZI 16* 
Cefotaxime, FOT 0.25  
Ceftazidime, TAZ 0.5  
Chloramphenicol, CHL 16 
Ciprofloxacin, CIP 0.064  
Colistin, COL 2 
Gentamicin, GEN 2 
Meropenem, MERO 0.125 
Nalidixic acid, NAL 16 
Sulfamethoxazole, SMX 64 
Tetracycline, TET 8 
Tigecycline, TGC 0.5** 
Trimethoprim, TMP 2 
* Tentative ECOFF  
** EUCAST.org 
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Plasmid-mediated quinolone resistance  
When performing antimicrobial susceptibility testing of E. coli, the interpretative criteria listed in 
Table 1 for results obtained by MIC-determination should allow detection of plasmid-mediated 
quinolone-resistant test strains.  
Beta-lactam resistance 
Confirmatory testing for ESBL production is mandatory on all strains resistant to cefotaxime 
(FOT), ceftazidime (TAZ) and/or meropenem (MERO) and should be performed by testing the 
second panel of antimicrobials  (Table 2). 
 
 
Table 2. Antimicrobials recommended for additional AST of Escherichia coli resistant to 
cefotaxime, ceftazidime or meropenem and interpretative criteria according to Table 4 in 
Commission Implementing Decision 2013/652/EU. 
 
Antimicrobials for E. coli MIC (g/mL) R is > 
Cefepime, FEP 0.125 
Cefotaxime, FOT  0.25 
Cefotaxime + clavulanic acid (F/C) Not applicable 
Cefoxitin, FOX 8 
Ceftazidime, TAZ 0.5 
Ceftazidime+ clavulanic acid (T/C) Not applicable 
Ertapenem, ETP 0.064 
Imipenem, IMI 0.5 
Meropenem, MERO 0.125 
Temocillin, TRM >32* 
*Tentative ECOFF  
Confirmatory test for ESBL production requires use of both cefotaxime (FOT) and ceftazidime 
(TAZ) alone and in combination with a -lactamase inhibitor (clavulanic acid). Synergy is defined 
either as i) a ≥ 3 twofold concentration decrease in an MIC for either antimicrobial agent tested in 
combination with clavulanic acid vs. the MIC of the agent when tested alone (MIC FOT : FOT/CL 
or TAZ : TAZ/CL ratio  8) (CLSI M100 Table 3A, Tests for ESBLs). The presence of synergy 
indicates ESBL production.  
Confirmatory test for carbapenemase production requires the testing of meropenem (MERO).  
Detection of AmpC-type beta-lactamases can be performed by testing the bacterium for 
susceptibility to cefoxitin (FOX). Resistance to FOX could indicate the presence of an AmpC-type 
beta-lactamase. 
The classification of the phenotypic results should be based on the most recent EFSA 
recommendations (EURL-AR Workshop 2016, http://www.crl-ar.eu/data/images/ws_april-
2016/f11_efsa_criteria.pdf and in the appendix to this protocol). 
 
Appendix 4 
Page 6 of 9 
Page 6 of 9 
  
 
4 REPORTING OF RESULTS AND EVALUATION 
Please write your results in the test forms, and enter your results into the interactive web database.  
 
4.1 General recommendations for data upload 
We recommend reading carefully the description reported in paragraph 5 before entering your 
results in the web database. Results must be submitted no later than 9th, December, 2015. After 
the deadline when all participants have uploaded results, you will be able to login to the database 
once again, and to view and print an automatically generated report evaluating your results. Results 
in agreement with the expected interpretation are categorised as ‘correct’, while results deviating 
from the expected interpretation are categorised as ‘incorrect’. 
If you experience difficulties in entering your results, please contact us directly.  
All results will be summarized in a report which will be publicly available. The data in the report 
will be presented with laboratory codes. A laboratory code is known to the individual laboratory, 
whereas the complete list of laboratories and their codes is confidential and known only to the 
EURL-AR and the EU Commission. All conclusions will be public. 
If you have questions, please do not hesitate to contact the EQAS Coordinator: 
Lina Cavaco 
National Food Institute 
Technical University of Denmark 
Søltofts Plads, Building 221, DK-2800 Lyngby 
Denmark 
Tel: +45 3588 6269 
Fax: +45 3588 6341 
E-mail: licav@food.dtu.dk 
 
5 HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE 
Please read carefully this paragraph before entering the web page. 
Remember that you need by your side the completed test forms.  
Enter the EURL-AR EQAS 2016 start web page (http://eurl.food.dtu.dk/matrix ), write your 
username and password in lower-cases and press enter. Your username and password are indicated 
in the Welcome letter following the samples. Do not hesitate to contact us if you experience 
problems with the login. 
You can browse back and forth by using the Home or back keys, but please remember to save your 
inputs before. 
5.1 Sample reception/testing 
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Please fill in with information in relation to date and time (please note the exact time) and 
temperature at arrival of the parcel contents as measured by you (we will also check on the thermo-
loggers data after you send back the device. 
5.2 Selective enrichment methods 
Please fill in with the details of the methods use and insert any changes made to the official method 
5.3 Test results  
 
5.3.1 Selective enrichment of presumptive ESBL- , AmpC- or carbapenemase -producing E. 
coli 
Fill in the answers for the questions regarding the selective enrichment results along the process 
 
5.3.2 Species identification enrichment of presumptive ESBL- or AmpC-producing E. coli 
Please confirm the results and conclude if you found an E. coli presumptive of producing an ESBL 
or AmpC gene in the sample (this conclusion will be evaluated). 
Please confirm the results and conclude also if you found an E. coli presumptive of producing a 
carbapenemase or OXA-type enzyme in the sample (these conclusions will be evaluated 
separately). 
If you respond to the above questions indicating that you did not find a presumptive isolate to go 
further you are not expected to fill in the remaining questions. 
If your answer is ‘yes’ for both or one of the above, you are expected to fill in the MIC tables and 
final conclusion of the AST and confirmatory testing. 
 
5.3.3 AST of E. coli 
Based on the first MIC panel results, indicate if the isolate fulfils the criteria to be tested on the 
second panel (confirmatory phenotypic testing) or not, and fill in the results for the second panel in 
case you decide to do the confirmatory testing. 
Complete the fields in the result tables related to the results obtained. 
Click on “save” and then go back using the tab “home” and enter another test page to upload results  
In the data entry pages, enter the obtained values and the interpretation (R, resistant or S, 
susceptible) for each E. coli isolate. 
Remember to report also the conclusion of the phenotypic testing on the second panel (will be 
evaluated separately). 
If you did not test for susceptibility to a given antimicrobial, please leave the field empty. 
Click on “save“ and then go back using the tab “home” and enter another test page to upload 
results.  
Click on “save“. 
5.4 Finalizing data input, EQAS evaluation and approval of result upload 
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Review the input pages by browsing through the pages and make corrections if necessary. 
Remember to save a page if you make corrections. If you press home a page without saving 
changes, you will see an error screen. In this case, click on “save“ to save your results, browse back 
to the page and then continue. 
Please complete the evaluation form for the EQAS when you finalize the data input. You can find 
the tab on the Home page, on the tab “Evaluation” 
Before approving your input, please be sure that you have filled in all the relevant fields for the 
sample sheet, the methods and the test results for all samples tested because YOU CAN ONLY 
APPROVE ONCE! The approval blocks your data entry in the interactive database. 
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APPENDIX 
 
Criteria for interpretation of Escherichia coli, panel 2 results 
 
 
 
 
 
Please refer to the full presentation at http://www.crl-ar.eu/data/images/ws_april-
2016/f11_efsa_criteria.pdf 
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Test forms, 
Isolation of ESBL/AmpC- and carbapenemase-producers from matrices 
 
 
Username:       
Contact person:                                
 
Country:       
Date for filling in test forms:            
 
 
 
 
SAMPLES 
 
Reception date and exact time of opening the parcel of the proficiency test samples at the 
laboratory:             (date and time is required) 
 
Temperature of the contents of the parcel at arrival:      °C 
 
 
How many samples did your laboratory process in 2016 for monitoring of ESBL/AmpC-detection in 
relation to 2013/652/EU? (choose only one option) 
 less than 100 
 101-200 
 201-300 
 301-400 
 401- 1000  
 more than 1000 
 
 
Which kind of samples did your laboratory process in 2016 for monitoring of ESBL/AmpC-detection 
in relation to 2013/652/EU? (you may choose more than one option) 
  caecal, poultry (chicken) 
  caecal, poultry (turkey) 
  meat, poultry (chicken) 
  other matrices, please specify:                      
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Did you process samples for carbapenemase-selective isolation?  
 Yes 
  No 
 
 
How many samples did your laboratory process in 2016 for monitoring of carbapenemases in 
relation to 2013/652/EU? (Choose only one option) 
 less than 100 
 101-200 
 201-300 
 301-400 
 401- 1000  
 more than 1000 
 
 
Which kind of samples did your laboratory process in 2016 for monitoring of carbapenemase-
production in relation to 2013/652/EU? (you may choose more than one option) 
  caecal, poultry (chicken) 
  caecal, poultry (turkey) 
  meat, poultry (chicken) 
  other matrices, please specify:                      
 
Any other comments:                                                    
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METHODS 
                                                        
1- Method used for selective isolation of ESBL/AmpC  in this EQAS:  
 
Selective isolation procedure using the EURL recommended protocols that refer to the EU 
regulation 652/2013/EU  
 
 The protocol was used without modifications (please jump to question 2) 
 The protocol was used, however, the pre-enrichment was modified (please respond 
question 1.1) 
 The protocol was used, however, the selective isolation procedures were modified (please 
respond question 1.2) 
 The protocol was used, however, the incubation conditions in the selective plating were 
modified (please respond question 1.3) 
 
 
1.1- If you modified the pre-enrichment, please indicate the differences introduced: 
 
 Different sample amount (weight) used for the enrichment procedure:  
       g in meat samples 
       g for caecal samples 
  
 Different volume of enrichment in the isolation step:  
       ml for meat samples 
       ml for caecal samples 
  
 Different pre-enrichment medium:      
Different incubation conditions in pre-enrichment      °C/     h;  
  
 Please justify these changes:      
 
  
 1.2- If you made changes in the selective isolation procedure: 
 
 Different sample amount (weight) used for the enrichment procedure:  
       g in meat samples 
       g for caecal samples 
 
 Different concentration of cefotaxime:        mg/l      
 Different antimicrobial               
 Different medium       
     Please justify these changes:      
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 1.3- If you used different incubation conditions in the selective 
plating, please indicate the conditions used:      °C/     h;  
   
 Please justify these changes:      
 
 
 
2- Method used for selective isolation of carbapenemase-producers (in case you run this 
method)  in this EQAS:  
 
Selective isolation procedure using the EURL recommended protocols for isolation of 
carbapenemase-producers: 
  We did not perform carbapenemase selective isolation 
  The protocol was used without modifications  
  The protocol was modified  
 
 Plates used (brand/type)       
 Please justify these changes:      
 
 
 
3- Method used for confirmation of E. coli species identification. Please indicate the primary E. 
coli identification method used (choose only one option; if you used more than one method, 
please explain in the comments field) 
 
 PCR using published methods 
 PCR using in-house method 
  Biochemical tests 
  Maldi-Tof  
  DNA Sequencing  
  Chromogenic media 
 
Comments:                                               
 
 
 
4- Method used for general antimicrobial susceptibility testing of the strains (choose only one 
option) 
 
 Microbroth dilution test on EUVSEC panel  
 Microbroth dilution test on another panel  
 Agar dilution method 
  E-test 
  Disk diffusion test 
 
 
 
 
5- Method used for phenotypic confirmatory testing of ESBL/AmpC (choose only one option) 
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 Microbroth dilution test on EUVSEC2 panel  
 Microbroth dilution test on another panel  
 Agar dilution method 
  E-test 
  Disk diffusion test 
 
 
 
6- Additional comments. Please include here description and justification of your choice if you 
modified something in relation to the method defined in the EU regulation 2013/652/EU: 
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TEST FORM – SAMPLE ‘EURL M-2.X’ 
 
Date the isolation procedure was started:        
 
Please describe the results you have observed regarding this sample: 
 
Visible growth in pre-enrichment:  
 Yes / No  
 
Growth on ESBL/AmpC-selective plates: 
 Yes  / No  
 
Please describe the growth observed on ESBL/AmpC-selective plates? (choose only one 
option) 
 Mixed culture containing typical E. coli colonies 
 Mixed culture without typical E. coli colonies 
 Pure culture of typical E. coli colonies 
 Pure culture without typical E. coli colonies 
 No growth 
 
Results of species identification: (choose only one option) 
 No isolates tested (sample negative) 
 Presumptive ESBL/AmpC isolate identified as E. coli (sample considered positive) 
Comments:                 
 
Did you perform carbapenemase selective plating? 
Yes  / No  
 
Growth on CARBA-selective plates: 
 Yes  / No  
 
Growth on OXA-48 selective plates: 
 Yes  / No  
 
 
Results of species identification (isolates from carbapenemase selective plating): (choose 
only one option) 
 No isolates tested (sample negative) 
 Presumptive other carbapenemase isolate identified as E. coli (sample considered positive) 
 Presumptive OXA-48 isolate identified as E. coli (sample considered positive) 
Comments:                 
 
If you have found a presumptive carbapenemase positive isolate, please insert the results 
of antimicrobial susceptibility testing for the selected E. coli isolate, if you do not have a 
carbapenemase positive isolate and you have an ESBL presumptive isolate, please insert 
the results for this isolate (only one E.coli isolate is expected to be tested and these results 
will be evaluated in our database against the expected results). 
 
Please confirm where the isolate tested for antimicrobial susceptibility originated from 
(compulsory): 
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 ESBL/ampC isolation on Mac Conkey with cefotaxime   
 CARBA plate   
 OXA-48 plate  
 
Based on the results from the first AST panel, was the isolate found resistant to cefotaxime, 
ceftazidime or meropenem so that the second panel was tested? 
  
Yes  /  No  
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AST results   
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
E. coli 
EURL  M-2.X 
Ampicillin, AMP                         
Azithromycin, AZI                   
Cefotaxime, FOT                    
Ceftazidime, TAZ                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Colistin, COL                   
Gentamicin, GEN                    
Meropenem, MERO                   
Nalidixic acid, NAL                    
Sulfamethoxazole, SMX                    
Tetracycline, TET                    
Tigecycline, TGC                   
Trimethoprim, TMP                    
 
Second E. coli AST panel (confirmatory testing for ESBL/AmpC/carbapenemase-production)                 
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
E. coli 
EURL M-2.X 
Cefepime, FEP                   
Cefotaxime + clavulanic acid (F/C)                   
Cefotaxime, FOT                   
Cefoxitin, FOX                   
Ceftazidime, TAZ                   
Ceftazidime+ clavulanic acid (T/C)                   
Ertapenem, ETP                   
Imipenem, IMI                   
Meropenem, MERO                   
Temocillin, TRM                   
Conclusions of confirmatory phenotypic testing: (choose only one option and please note that the final 
result will be evaluated by the database) 
 
Interpretation of PANEL 2 results: 
 Presumptive ESBL 
 Presumptive ESBL+ AmpC 
 Presumptive AmpC 
 Presumptive carbapenemase 
 
 Other phenotype 
 Susceptible 
 
 
Comments (include optional genotype or other results):       
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